Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,061 stopped studies mapped to Malignant Neoplasm of Unknown Primary and descendants · 91% state a reason
Over the 2,061 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03300401 | Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing… | N/A | withdrawn | Oct 3, 2017 | University of Southern California | Accrual issue | Enrollment / accrual |
| NCT01290523 | Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With… | N/A | terminated | Feb 7, 2011 | University of California, San Francisco | Off study clinical use of Y90 glass microspheres (TheraSphere) | Other (stated, no rule matched) |
| NCT03388931 | Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or… | Phase 4 | withdrawn | Jan 3, 2018 | University of Florida | lack of subject enrollment | Enrollment / accrual |
| NCT02817607 | Study to Assess Breast Sensation Before and After Breast Cancer Treatment | N/A | withdrawn | Jun 29, 2016 | Duke University | not stated | Not stated |
| NCT03775707 | Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria | Phase 2 | withdrawn | Dec 14, 2018 | Shi Ming | Protocol modification | Other (stated, no rule matched) |
| NCT03780634 | HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC | Phase 2 | withdrawn | Dec 19, 2018 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03803254 | HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC | Phase 2 | withdrawn | Jan 14, 2019 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT00727532 | Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | N/A | terminated | Aug 4, 2008 | Northwestern University | Low Accrual | Enrollment / accrual |
| NCT03744247 | Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC | Phase 3 | withdrawn | Nov 16, 2018 | Sun Yat-sen University | No paritcipants enrolled | Enrollment / accrual |
| NCT03782831 | TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC | Phase 2 | withdrawn | Dec 20, 2018 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03791918 | Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven… | Phase 3 | withdrawn | Jan 3, 2019 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT02720484 | Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer | Phase 2 | terminated | Mar 28, 2016 | Northwestern University | Study did not meet first stage requirements of interim analysis | Efficacy / futility |
| NCT02078752 | A Study Of PF-06647263 In Patients With Advanced Solid Tumors | Phase 1 | terminated | Mar 5, 2014 | Pfizer | The study was terminated due to a change in sponsor prioritization. | Other (stated, no rule matched) |
| NCT03644589 | Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable… | Phase 2 | withdrawn | Aug 23, 2018 | University of Washington | No participants enrolled. | Enrollment / accrual |
| NCT03325465 | Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell… | Phase 2 | withdrawn | Oct 30, 2017 | University of Chicago | Site decided not to move forward with trial. Study never opened to enrollment. | Enrollment / accrual |
| NCT00507702 | Identification of Key Blood Molecular Markers for Immunotherapy | — | terminated | Jul 26, 2007 | Stanford University | Improving assay methods | Other (stated, no rule matched) |
| NCT02341170 | HS-PCI in Locally Advanced Adenocarcinoma of the Lung(HIPPO-S) | N/A | withdrawn | Jan 19, 2015 | Universitätsmedizin Mannheim | Lack of Funding | Funding |
| NCT03746249 | Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC | Phase 2 | withdrawn | Nov 19, 2018 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT02706691 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | Phase 2 | terminated | Mar 11, 2016 | University of Chicago | Study stopped due to poor enrollment. | Enrollment / accrual |
| NCT01676194 | Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma(CATCH) | Phase 3 | terminated | Aug 30, 2012 | Rennes University Hospital | insufficient recruitment | Enrollment / accrual |
| NCT03114280 | Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH…(PICH) | Phase 1 / Phase 2 | withdrawn | Apr 14, 2017 | Centre Antoine Lacassagne | MSD would not able to support the study's continuation after protocol modifications required by… | Other (stated, no rule matched) |
| NCT03122548 | Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction… | Phase 2 | terminated | Apr 21, 2017 | Aduro Biotech, Inc. | Low enrollment and lack of clinical activity in other CRS-207 studies. | Enrollment / accrual |
| NCT02950025 | Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary… | Phase 2 | terminated | Oct 31, 2016 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT02610920 | Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using… | Early Phase 1 | withdrawn | Nov 20, 2015 | Columbia University | Unable to enroll subjects | Enrollment / accrual |
| NCT02542137 | Abscopal Effect for Metastatic Small Cell Lung Cancer | Phase 2 | withdrawn | Sep 4, 2015 | Zhejiang Provincial People's Hospital | No recruitment. | Enrollment / accrual |
| NCT02782182 | Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot… | Phase 1 | terminated | May 25, 2016 | University of Chicago | Closed early due to poor accrual. | Enrollment / accrual |
| NCT01760252 | Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol | Phase 2 | terminated | Jan 4, 2013 | Beth Israel Medical Center | not stated | Not stated |
| NCT00784329 | Pilot Study To Evaluate Optical Frequency Domain Imaging For Diagnosis Of Central Airway… | N/A | withdrawn | Nov 3, 2008 | Lahey Clinic | not stated | Not stated |
| NCT01198158 | Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer… | Phase 3 | terminated | Sep 9, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02867332 | PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma. | Phase 1 | withdrawn | Aug 15, 2016 | Peking University | No funding | Funding |
| NCT01502228 | PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma | N/A | terminated | Dec 30, 2011 | Indiana University | No further funding | Funding |
| NCT01163084 | Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in… | Phase 1 / Phase 2 | terminated | Jul 15, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02267213 | Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma | Phase 2 | terminated | Oct 17, 2014 | Taiwan Liposome Company | Current study design couldn't support futher development on this indication | Other (stated, no rule matched) |
| NCT03179956 | Impact of Ribociclib on Head and Neck Squamous Cell Cancer | Early Phase 1 | terminated | Jun 7, 2017 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT02050009 | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent… | Phase 1 | withdrawn | Jan 30, 2014 | Fox Chase Cancer Center | study was never opened to accrual | Enrollment / accrual |
| NCT00465842 | Protein Biomarker in Hepatocellular Carcinoma | — | terminated | Apr 25, 2007 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Loss of funding due to difficulty with recruitment and participant retention. | Enrollment / accrual |
| NCT00969306 | Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients(Chloroquine IV) | Phase 1 | terminated | Sep 1, 2009 | Maastricht Radiation Oncology | Poor accrual | Enrollment / accrual |
| NCT01484860 | Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line… | Phase 2 | terminated | Dec 2, 2011 | University Health Network, Toronto | not stated | Not stated |
| NCT02748304 | Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With… | N/A | terminated | Apr 22, 2016 | Fudan University | The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose… | Enrollment / accrual |
| NCT01115803 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | Phase 1 | terminated | May 4, 2010 | Eli Lilly and Company | Primary objective has been met; safety and pharmacokinetics have been characterized. | Safety / toxicity |
| NCT02891733 | Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung…(NTS) | — | withdrawn | Sep 7, 2016 | Fondation Hôpital Saint-Joseph | The principal investigator decided to stop the study. | Investigator |
| NCT03346304 | Photodynamic Therapy for the Prevention of Lung Cancer(PEARL) | Phase 2 / Phase 3 | withdrawn | Nov 17, 2017 | University College, London | drug no longer available | Other (stated, no rule matched) |
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2016 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT02570529 | Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally… | Phase 4 | withdrawn | Oct 7, 2015 | Yonsei University | Investigator decided to stop the study because it was difficult to proceed with the study. | Investigator |
| NCT02388932 | Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced… | N/A | terminated | Mar 17, 2015 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01600196 | Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous… | Phase 4 | terminated | May 16, 2012 | Sun Yat-sen University | not stated | Not stated |
| NCT01994213 | A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic… | Phase 2 | terminated | Nov 25, 2013 | Jiangsu HengRui Medicine Co., Ltd. | The applicant decided to close the study | Other (stated, no rule matched) |
| NCT02205398 | Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and… | Phase 1 | terminated | Jul 31, 2014 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT03147196 | Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer… | Phase 2 | withdrawn | May 10, 2017 | Mayo Clinic | lack of accrual | Enrollment / accrual |
| NCT02220088 | The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a… | Phase 2 / Phase 3 | terminated | Aug 19, 2014 | Sun Yat-sen University | protocol violation | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated May 16, 2019source: clinicaltrials